Xencor, Inc.
NASDAQ•XNCR
CEO: Dr. Bassil I. Dahiyat Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2013-12-03
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
Contact Information
Market Cap
$913.34M
P/E (TTM)
-6.9
38.2
Dividend Yield
--
52W High
$21.00
52W Low
$6.92
52W Range
Rank46Top 59.5%
3.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$21.00M+18.00%
4-Quarter Trend
EPS
-$0.08-88.73%
4-Quarter Trend
FCF
-$31.00M+10.16%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Nine Month Revenue Jumps Total revenues reached $97.34M, marking a substantial $39.64M increase for the nine months ended September 30, 2025.
Net Loss Significantly Narrows Net loss attributable to Xencor improved by $104.97M to $(85.27M) for nine months, reflecting strong operational leverage.
Regulatory Milestones Trigger Payments FDA approval for Incyte drug triggered $25.0M milestone payment in Q3 2025; Vir Bio Phase 3 initiation added $2.0M.
XmAb819 Shows Activity XmAb819 Phase 1 data showed 25% partial response rate in advanced ccRCC patients across 15 dose cohorts presented.
Risk Factors
Internal Control Material Weakness Material weakness found in controls over royalty sale accounting and tax legislation evaluation resulted in prior restatements.
Merus Patent Litigation Risk Ongoing patent infringement suit by Merus remains, despite motion to dismiss granted; ultimate outcome uncertain despite strong defenses.
Clinical Stage Funding Needs Company remains in clinical stage, expecting to increase operating expenses; current resources fund operations through next twelve months.
Global Economic Volatility Risk Unfavorable global economic or political conditions could cause capital market volatility, straining supply chains and capital raising ability.
Outlook
Advance Pipeline Programs Plan to initiate first-in-human study for XmAb657 by year end 2025; XmAb942 Phase 2b study in UC initiated Q3 2025.
Remediate Internal Control Issues Management committed to implementing comprehensive remediation actions for material weaknesses, subject to control operation testing period.
Expect Partner Payments Expect continued milestone and royalty payments from collaborators; receipt timing depends on achieving development and commercialization events.
Evaluate Tax Legislation Impact Preliminary evaluation of the One Big Beautiful Bill Act suggests no material change to effective tax rate due to full valuation allowance.
Peer Comparison
Revenue (TTM)
ANAB$169.47M
$167.36M
PHAT$147.19M
Gross Margin (Latest Quarter)
100.0%
100.0%
99.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TNGX | $1.44B | -14.4 | -60.8% | 16.5% |
| PGEN | $1.32B | -5.3 | -3342.6% | 57.3% |
| RLAY | $1.27B | -4.3 | -42.9% | 5.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-33.1%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Feb 26, 2026
EPS:-$0.64
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 5, 2025|Revenue: $21.00M+18.0%|EPS: $-0.08-88.7%MeetForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 6, 2025|Revenue: $43.61M+157.1%|EPS: $-0.41-61.7%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 7, 2025|Revenue: $32.73M+104.6%|EPS: $-0.66-40.5%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 27, 2025|Revenue: $110.49M-36.7%|EPS: $-3.58-72.1%MissForm 10-K/A - FY 2023
Period End: Dec 31, 2023|Filed: Feb 24, 2025|Revenue: $168.34M+2.3%|EPS: $-2.08-123.7%MissForm 10-Q/A - Q1 2024
Period End: Mar 31, 2024|Filed: Feb 24, 2025|Revenue: $16.00M-15.6%|EPS: $-1.11+11.0%MissForm 10-Q/A - Q2 2024
Period End: Jun 30, 2024|Filed: Feb 24, 2025|Revenue: $16.96M-62.7%|EPS: $-1.07+189.2%MissForm 10-Q/A - Q3 2024
Period End: Sep 30, 2024|Filed: Feb 24, 2025|Revenue: $17.80M-69.9%|EPS: $-0.71+77.5%Beat